Los Angeles Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Los Angeles Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$522K	Sell	20,635 -29,299	-59%	-$645K	﹤0.01%	904
2026 Q1	$1.11M	Buy	49,934 +138	+0.3%	+$3.3K	﹤0.01%	648
2025 Q4	$1.13M	Sell	49,796 -14,152	-22%	-$338K	﹤0.01%	586
2025 Q3	$1.36M	Sell	63,948 -1,209	-2%	-$28.6K	﹤0.01%	611
2025 Q2	$1.41M	Sell	65,157 -76,900	-54%	-$1.43M	0.01%	548
2025 Q1	$2.36M	Buy	142,057 +27,522	+24%	+$500K	0.01%	375
2024 Q4	$2.1M	Buy	114,535 +70,238	+159%	+$1.13M	0.01%	441
2024 Q3	$681K	Sell	44,297 -6,672	-13%	-$111K	﹤0.01%	776
2024 Q2	$828K	Sell	50,969 -16,505	-24%	-$266K	﹤0.01%	719
2024 Q1	$1.25M	Buy	67,474 +2,295	+4%	+$56.9K	﹤0.01%	622
2023 Q4	$2.04M	Buy	65,179 +19,871	+44%	+$475K	0.01%	479
2023 Q3	$944K	Buy	45,308 +3,771	+9%	+$102K	﹤0.01%	660
2023 Q2	$995K	Buy	41,537 +16,093	+63%	+$358K	﹤0.01%	656
2023 Q1	$479K	Buy	+25,444	New	+$485K	﹤0.01%	863
2021 Q2	–	Sell	-16,458	Closed	-$425K	–	1519
2021 Q1	$425K	Sell	16,458 -24,580	-60%	-$1.08M	﹤0.01%	1286
2020 Q4	$2.19M	Sell	41,038 -5,025	-11%	-$249K	0.01%	626
2020 Q3	$1.9M	Sell	46,063 -31,641	-41%	-$1.37M	0.01%	586
2020 Q2	$3.77M	Buy	77,704 +12,374	+19%	+$594K	0.02%	458
2020 Q1	$2.76M	Buy	65,330 +20,297	+45%	+$836K	0.02%	461
2019 Q4	$1.93M	Buy	45,033 +3,574	+9%	+$155K	0.01%	652
2019 Q3	$1.49M	Buy	41,459 +25,739	+164%	+$780K	0.01%	706
2019 Q2	$420K	Sell	15,720 -17,325	-52%	-$443K	﹤0.01%	1096
2019 Q1	$887K	Buy	+33,045	New	+$772K	﹤0.01%	893
2018 Q3	–	Sell	-450,345	Closed	-$6.88M	–	1378
2018 Q2	$6.88M	Buy	+450,345	New	+$8.03M	0.04%	427
2015 Q2	–	Sell	-12,775	Closed	-$416K	–	1200
2015 Q1	$416K	Buy	+12,775	New	+$439K	﹤0.01%	974

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Los Angeles Capital Management's ACAD Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Acadia Pharmaceuticals (ACAD) stake by 59% in Q2 2026, selling an estimated $645K and leaving 20,635 shares worth $522K. The position accounts for ﹤0.01% of the portfolio, ranked #904.

Los Angeles Capital Management first reported a position in ACAD in Q1 2015 and has held it in 25 quarters since. The position peaked at $6.88M in Q2 2018. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Los Angeles Capital Management held 20,635 shares of Acadia Pharmaceuticals worth $522K as of Q2 2026.
Los Angeles Capital Management sold 29,299 Acadia Pharmaceuticals shares in Q2 2026, an estimated $645K.
Acadia Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #904 holding.
Los Angeles Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2015 and has held it in 25 quarters since.
Los Angeles Capital Management's Acadia Pharmaceuticals position peaked at $6.88M in Q2 2018.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.